Results 171 to 180 of about 48,812 (228)

First-Line Nivolumab Plus Ipilimumab in Inoperable Epithelioid Malignant Pleural Mesothelioma: Real-World Experience From an Indian Tertiary Care Center. [PDF]

Cureus
Shah A, Agarwal A, Rajpuria V, Ghodasara S, Swami J, Kanth V, Dangar H, Jakhetiya A.   +7 more
europepmc   +1 more source

Comparison of Long-Term Survival Between Nivolumab Plus Ipilimumab and Nivolumab Plus Ipilimumab With Chemotherapy in Advanced NSCLC: A Multicenter Retrospective Cohort Study. [PDF]

JTO Clin Res Rep
Komuta K, Matsumoto K, Tamiya M, Shiroyama T, Kinehara Y, Tamiya A, Kuge T, Uchida J, Suzuki H, Yamamoto S, Tobita S, Niki T, Tetsumoto S, Morimura O, Osa A, Minami T, Nishino K, Takeda Y, Kumanogoh A.   +18 more
europepmc   +1 more source

Management of Advanced Solid Tumors Recurring After Adjuvant Immune Checkpoint Inhibitors: A Structured Narrative Review. [PDF]

Curr Oncol
Petrelli F, Dottorini L, Ghidini A, Zambelli A.   +3 more
europepmc   +1 more source

Clinical and Biochemical Recovery From Immune Checkpoint Inhibitor-Induced Diabetes With Seroconversion of GAD Antibodies. [PDF]

Diabetes Care
Chen LR, Cooksley T, Kochhar R, Titus Raj EJ, Lorigan P, Adam S.   +5 more
europepmc   +1 more source

Survival in unresectable hepatocellular carcinoma: Comparison of four treatments based on patients reconstructed from Kaplan-Meier curves of randomized trials. [PDF]

World J Gastrointest Pharmacol Ther
Damuzzo V, Vecchia S, Gasperoni L, Del Bono L, Ossato A, Orlandi E, Messori A.   +6 more
europepmc   +1 more source

Complete response to dual immune checkpoint blockade in a patient with Birt-Hogg-Dubé syndrome and epithelioid angiomyolipoma. [PDF]

J Immunother Cancer
Viola J, Cornish A, Carlo MI, Hamid A, Reuter VE, Russo P, Motzer RJ, Voss MH, Kotecha RR.   +8 more
europepmc   +1 more source

Cancer-related fatigue during treatment with neoadjuvant and/or adjuvant immune checkpoint inhibitors: a systematic review and meta-analysis. [PDF]

Support Care Cancer
Potter L, Lopez-Olivo MA, Uppal RS, Beeler D, Thong MSY, Phan B, Chou YJ, Krause K, Tanveer A, Hussain HU, Khan M, Abdel-Wahab N, Manzullo E, Kleckner AS, Escalante C.   +14 more
europepmc   +1 more source

The Feasibility of Combining Cost-Effectiveness, Bayesian Meta-Analysis and Meta-Regression Techniques When Evaluating Melanoma Treatment Methods. [PDF]

Onco Targets Ther
Gąska I, Czerw A, Pajewska M, Partyka O, Charkiewicz D, Kaczmar E, Sygit K, Sygit M, Dziubek IT, Wojtyła-Buciora P, Drobnik J, Pobrotyn P, Waśko-Czopnik D, Sowiński T, Tejza K, Grata-Borkowska U, Strzępek Ł, Curyło M, Zawadzka M, Grochans E, Cybulska AM, Schneider-Matyka D, Rachubińska K, Bandurska E, Ciećko W, Czerw N, Marczak M, Borzuchowska M, Kozlowski R.   +28 more
europepmc   +1 more source

Evaluation of the flipped dose NIVO3+IPI1 in patients with advanced unresectable melanoma. [PDF]

J Natl Cancer Inst
Björkström K, Liu C, Fager A, Liu LL, Ny L, Helgadottir H.   +5 more
europepmc   +1 more source

Haemophagocytic Lymphohistiocytosis Following Ipilimumab and Nivolumab in Malignant Pleural Mesothelioma: A Case Report. [PDF]

Cureus
Than CM, Moe M, Win Y, Maung K.
europepmc   +1 more source